Evotec SE
EVT.SW
Swiss Exchange5.04
EUR
+0.03
- -
ISIN
DE0005664809
Return %
Stock
S&P500
1Y
26.83
26.84
3Y
26.83
77.03
5Y
-81.66
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Mario Polywka DPHIL,
- Full Time Employees
- 5,055
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Essener Bogen 7 Hamburg Germany 22419
- IPO Date
- Nov 4, 2014
- Website
- evotec.com
- Similar Companies
- Business
- Evotec SE functions as a dedicated partner for integrated drug discovery and development across the global pharmaceutical and biotechnology sectors. The company provides comprehensive solutions from target identification through clinical advancement, leveraging its extensive platforms in small molecules, biologics, and cell therapies. Evotec's expertise spans a broad range of therapeutic categories, including oncology, neurological and metabolic conditions, autoimmune disorders, inflammation, pain, infectious diseases, and rare diseases, among others. The company's unique approach integrates cutting-edge technologies like proprietary molecular patient databases, PanOmics, iPSC-based disease modeling, and AI/ML-driven discovery platforms to enhance the probability of success in developing new medicines. Evotec maintains a wide network of collaborations, partnering with major pharmaceutical companies, biotechnology firms, and academic institutions. Recent alliances include a significant agreement with Sandoz AG for the sale of its Just – Evotec Biologics Toulouse site, potentially yielding over US$650 million plus future royalties on biosimilars. The company also expanded its strategic neuroscience partnership with Bristol Myers Squibb, receiving milestone payments for scientific progress and IND acceptances. Additionally, Evotec forged a technology development partnership with Novo Nordisk in cell therapy. In April 2025, Evotec unveiled a new strategy, "Priority Reset," to streamline its business model, reinforce its technology and science leadership, and target sustainable profitable growth, aiming for annualized gross savings. Originally incorporated in 1993, the company transitioned its name from Evotec AG to Evotec SE in April 2019 and is headquartered in Hamburg, Germany.